BioLucent
	Operator of women\'s health company, involved in the early detection and treatment of breast cancer. The company manufactures and markets the MammoPad breast cushion, a radiolucent foam cushion that breast centers use to provide women with a mammogram.
	['', 'breast cancer', ' ', 'MammoPad breast cushion', ' ', 'radiolucent cushion', '']
Paradigm Therapeutics
	Developer of drugs combining model genetics and bioinformatics. The company provides target identification and validation services based on gene knock out technology and in vivo pharmacology. The company has developed a drug discovery pipeline comprising targets and late stage pre-clinical projects in pain, CNS disorders, hormone dependent diseases such as prostate and breast cancer and metabolic diseases such as diabetes, hyperlipidemias, obesity and osteoporosis.
	['', 'hormone dependent diseases', ' bioinformatics ', 'model genetics', ' ', 'validation services', '']
Orthotopix
	Developer of modelling products for cancer research. The company is a provider of cell, tissue and animal models modelling the prevention and treatment of breast cancer and prostate cancer, urodynamical models of urethral function and a cell line-based safety model of the endometrium. The company provided its products and services to drug-development companies.
	['', 'drug development', ' ', 'healthcare service', ' ', 'tissue modeling', '']
Endocyte
	Developer of receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug.
	['', 'cancer treatment', ' ', 'autoimmune disease', ' ', 'ovarian cancer', ' ', 'breast cancer', '']
Seragon Pharmaceuticals
	Developer of orally active selective estrogen receptor degraders (SERDs) that represent a treatment for metastatic breast cancer. The company is developing breast cancer pharmaceuticals based on the selective estrogen receptor degraders platform, including its lead drug candidate, ARN-810, under evaluation for ER+ breast cancer.
	['', 'breast cancer', ' ', 'estrogen receptor degrader', ' metastatic']
Suomen Terveystutkimus
	Provider of breast-cancer screening products and services. The company develops products and performs mammography screenings along with other clinical tests, to detect and treat breast cancer.
	['', 'breast cancer', ' ', 'mammography screening', ' ', 'cancer treatment', '']
Ziopharm
	Developer of drug candidates for cancer treatments. The company operates with the strategy of in-licensing proprietary drug-candidate families with prior ""related-molecule" efficacy in human cancer that could be efficiently and effectively developed and commercialized.
	['', 'cancer therapeutics', ' ', 'molecule therapeutic', ' ', 'healthcare service', '']
NaniRx Therapeutics
	Developer of Precision Immune-Stimulants for the treatment of breast cancer and on Precision Tolerogens for the treatment of autoimmune disorders.
	['', 'drug development', ' ', 'autoimmune disorder', ' ', 'cancer treatment', '']
Windy Hill Medical
	Developer of medical devices to reduce the risk of developing breast cancer in high risk patients. The company intends to develop intraductal therapy for the prevention of breast cancer.
	['', 'breast cancer', '']
